ATE454465T1 - In-vitro-verfahren zur identifizierung von verbindungen zur krebstherapie - Google Patents
In-vitro-verfahren zur identifizierung von verbindungen zur krebstherapieInfo
- Publication number
- ATE454465T1 ATE454465T1 AT06725852T AT06725852T ATE454465T1 AT E454465 T1 ATE454465 T1 AT E454465T1 AT 06725852 T AT06725852 T AT 06725852T AT 06725852 T AT06725852 T AT 06725852T AT E454465 T1 ATE454465 T1 AT E454465T1
- Authority
- AT
- Austria
- Prior art keywords
- cancer
- individual
- vitro method
- identifying
- cancer therapy
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 238000000338 in vitro Methods 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 238000011275 oncology therapy Methods 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 4
- 201000011510 cancer Diseases 0.000 abstract 4
- 230000000694 effects Effects 0.000 abstract 3
- 238000002560 therapeutic procedure Methods 0.000 abstract 2
- 206010005003 Bladder cancer Diseases 0.000 abstract 1
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 102100031065 Choline kinase alpha Human genes 0.000 abstract 1
- 101710106334 Choline kinase alpha Proteins 0.000 abstract 1
- 206010009944 Colon cancer Diseases 0.000 abstract 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 abstract 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 abstract 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 abstract 1
- 210000000481 breast Anatomy 0.000 abstract 1
- 230000006303 immediate early viral mRNA transcription Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 210000004072 lung Anatomy 0.000 abstract 1
- 201000005202 lung cancer Diseases 0.000 abstract 1
- 208000020816 lung neoplasm Diseases 0.000 abstract 1
- 229940126601 medicinal product Drugs 0.000 abstract 1
- 238000012544 monitoring process Methods 0.000 abstract 1
- 201000005112 urinary bladder cancer Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
- C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57423—Specifically defined cancers of lung
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES200500875 | 2005-04-13 | ||
| PCT/ES2006/070047 WO2006108905A1 (es) | 2005-04-13 | 2006-04-12 | Método in vitro para identificar compuestos para terapia del cáncer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE454465T1 true ATE454465T1 (de) | 2010-01-15 |
Family
ID=37087793
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT06725852T ATE454465T1 (de) | 2005-04-13 | 2006-04-12 | In-vitro-verfahren zur identifizierung von verbindungen zur krebstherapie |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US8481256B2 (de) |
| EP (2) | EP1889920B1 (de) |
| JP (1) | JP4759612B2 (de) |
| KR (3) | KR101352142B1 (de) |
| CN (3) | CN101405403B (de) |
| AT (1) | ATE454465T1 (de) |
| BR (1) | BRPI0607507A2 (de) |
| CA (1) | CA2604803A1 (de) |
| DE (1) | DE602006011607D1 (de) |
| DK (1) | DK1889920T3 (de) |
| ES (1) | ES2341729T3 (de) |
| MX (1) | MX2007012668A (de) |
| PL (1) | PL1889920T3 (de) |
| PT (1) | PT1889920E (de) |
| RU (1) | RU2434946C2 (de) |
| WO (1) | WO2006108905A1 (de) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2025686A4 (de) | 2006-05-29 | 2009-12-23 | Consejo Superior Investigacion | Monoklonale alpha-anticholin-kinase-antikörper und iher verwendung für analytische verfahren zur diagnose von krebs und zur herstellung von medizinprodukten |
| EP2271325A4 (de) | 2008-04-11 | 2011-11-09 | Cytotech Labs Llc | Verfahren und verfwendung zur einleitung von apoptose bei krebszellen |
| CA2729857A1 (en) * | 2008-07-04 | 2010-01-07 | Traslational Cancer Drugs Pharma, S.L. | Methods for the treatment and diagnosis of cancer |
| US20100068302A1 (en) * | 2008-09-17 | 2010-03-18 | Traslational Cancer Drugs Pharma, S.L. | Methods and compositions for the treatment of cancer |
| BR112013032857A2 (pt) * | 2011-06-20 | 2017-01-24 | Traslational Cancer Drugs Pharma S L | método para prever a resposta clínica à quimioterapia em um indivíduo com câncer |
| JP2013230145A (ja) * | 2012-04-30 | 2013-11-14 | Masahiko Sato | 細胞集団の状態を評価するための方法、候補化合物の発癌性を評価するための方法、潜在的な抗癌化合物の抗癌活性を評価するための方法及び治療用細胞集団の品質を評価するための方法 |
| KR102702287B1 (ko) | 2012-05-15 | 2024-09-04 | 브리스톨-마이어스 스큅 컴퍼니 | Pd-1/pd-l1 신호전달을 방해하는 것에 의한 암 면역요법 |
| WO2015028662A1 (en) | 2013-08-30 | 2015-03-05 | Consejo Superior De Investigaciones Cientificas (Csic) | Compositions and methods for characterization and amelioration of rheumatoid arthritis |
| RU2552305C1 (ru) * | 2014-04-04 | 2015-06-10 | Федеральное государственное бюджетное учреждение науки Институт физиологии природных адаптаций Уральского отделения Российской академии наук | Способ прогнозирования риска развития злокачественных новообразований |
| RS66622B1 (sr) | 2015-10-08 | 2025-04-30 | Zymeworks Bc Inc | Antigen-vezujući polipeptidni konstrukti koji sadrže kapa i lambda lake lance, i njihove upotrebe |
| RU2657417C1 (ru) * | 2017-05-29 | 2018-06-13 | Государственное бюджетное учреждение здравоохранения Московской области "Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского" (ГБУЗ МО МОНИКИ им. М.Ф. Владимирского) | Способ прогнозирования риска озлокачествления узловых образований у больных с эндокринологическими заболеваниями |
| RU2713795C1 (ru) * | 2019-06-13 | 2020-02-07 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Самарский государственный медицинский университет" Министерства здравоохранения Российской Федерации | Способ прогнозирования возможности озлокачествления опухоли яичника у женщин репродуктивного возраста |
| CN113391069B (zh) * | 2021-05-31 | 2023-10-27 | 浙江大学 | 基于CHKα的非代谢功能作为癌症治疗、诊断和预后预测之靶标的应用 |
| WO2025196502A1 (en) | 2024-03-20 | 2025-09-25 | North Carolina Agricultural & Technical State University | Choline kinase inhibitors as a therapeutic treatment for obesity |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| JPH05243020A (ja) * | 1992-03-02 | 1993-09-21 | Rohm Co Ltd | チップネットワーク型抵抗器 |
| EP0654092B1 (de) | 1992-06-26 | 2003-09-10 | The Trustees Of Princeton University | Verfahren zur erkennung von krebszellen oder ihren vorstadien mittels p90 und p53-antikörper oder p90 und p53-sonden |
| EP0854923A2 (de) | 1995-08-09 | 1998-07-29 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Isolierte nukleinsäuremolekulen an zu wenden als leukemiamarker und in brustkrebs prognosis |
| JP3756612B2 (ja) * | 1997-03-18 | 2006-03-15 | ローム株式会社 | チップ型抵抗器の構造及びその製造方法 |
| EP1018750A4 (de) * | 1997-07-03 | 2008-02-27 | Matsushita Electric Industrial Co Ltd | Widerstand und sein herstellungsverfahren |
| US20030077568A1 (en) | 2000-09-15 | 2003-04-24 | Gish Kurt C. | Methods of diagnosis of colorectal cancer, compositions and methods of screening for colorectal cancer modulators |
| JP4078042B2 (ja) * | 2001-06-12 | 2008-04-23 | ローム株式会社 | 複数の素子を有するチップ型電子部品の製造方法 |
| JP3846312B2 (ja) * | 2002-01-15 | 2006-11-15 | 松下電器産業株式会社 | 多連チップ抵抗器の製造方法 |
| US20030186241A1 (en) | 2002-03-20 | 2003-10-02 | Ken-Shwo Dai | Human choline/ethanolamine kinase (HCEK)-related gene variant associated with lung cancers |
| US20040115656A1 (en) | 2002-12-16 | 2004-06-17 | Tai-Jay Chang | Treating breast cancer |
| RU2246248C1 (ru) * | 2003-06-16 | 2005-02-20 | Ростовский научно-исследовательский онкологический институт МЗ РФ | Способ прогнозирования развития метахронного рака молочной железы |
| JPWO2005001089A1 (ja) | 2003-06-27 | 2006-11-02 | 生化学工業株式会社 | 癌の検出方法 |
| JP2005073548A (ja) | 2003-08-29 | 2005-03-24 | National Cancer Center-Japan | 卵巣明細胞腺癌の検査、治療、および治療薬のスクリーニングのための、ＨＮＦ−１βの利用 |
| ES2277568B1 (es) | 2005-12-30 | 2008-04-01 | Consejo Superior De Investigaciones Cientificas | Derivados de triterpenoquinona y triterpenofenoles y su aplicacion para el tratamiento de tumores y enfermedades parasitarias. |
-
2006
- 2006-04-12 CN CN2006800180309A patent/CN101405403B/zh not_active Expired - Fee Related
- 2006-04-12 KR KR20077026322A patent/KR101352142B1/ko not_active Expired - Fee Related
- 2006-04-12 MX MX2007012668A patent/MX2007012668A/es active IP Right Grant
- 2006-04-12 DE DE200660011607 patent/DE602006011607D1/de active Active
- 2006-04-12 PT PT06725852T patent/PT1889920E/pt unknown
- 2006-04-12 AT AT06725852T patent/ATE454465T1/de active
- 2006-04-12 CA CA 2604803 patent/CA2604803A1/en not_active Abandoned
- 2006-04-12 PL PL06725852T patent/PL1889920T3/pl unknown
- 2006-04-12 DK DK06725852T patent/DK1889920T3/da active
- 2006-04-12 EP EP20060725852 patent/EP1889920B1/de not_active Not-in-force
- 2006-04-12 BR BRPI0607507-0A patent/BRPI0607507A2/pt not_active IP Right Cessation
- 2006-04-12 WO PCT/ES2006/070047 patent/WO2006108905A1/es not_active Ceased
- 2006-04-12 CN CN2011101010882A patent/CN102228689A/zh active Pending
- 2006-04-12 ES ES06725852T patent/ES2341729T3/es active Active
- 2006-04-12 JP JP2008505911A patent/JP4759612B2/ja not_active Expired - Fee Related
- 2006-04-12 RU RU2007141930A patent/RU2434946C2/ru not_active IP Right Cessation
- 2006-04-12 CN CN2013100987593A patent/CN103215351A/zh active Pending
- 2006-04-12 US US11/911,513 patent/US8481256B2/en not_active Expired - Fee Related
- 2006-04-12 KR KR1020127031248A patent/KR101322705B1/ko not_active Expired - Fee Related
- 2006-04-12 EP EP10150087.4A patent/EP2246441B1/de not_active Not-in-force
- 2006-04-12 KR KR1020137014648A patent/KR20130086060A/ko not_active Abandoned
-
2011
- 2011-05-02 US US13/099,195 patent/US8901096B2/en not_active Expired - Fee Related
-
2013
- 2013-06-06 US US13/911,753 patent/US20140023657A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US8481256B2 (en) | 2013-07-09 |
| CN103215351A (zh) | 2013-07-24 |
| RU2434946C2 (ru) | 2011-11-27 |
| KR101322705B1 (ko) | 2013-10-29 |
| KR20130086060A (ko) | 2013-07-30 |
| KR101352142B1 (ko) | 2014-02-17 |
| CN102228689A (zh) | 2011-11-02 |
| US20090304575A1 (en) | 2009-12-10 |
| EP2246441A1 (de) | 2010-11-03 |
| KR20130006703A (ko) | 2013-01-17 |
| DK1889920T3 (da) | 2010-05-10 |
| JP2008535511A (ja) | 2008-09-04 |
| ES2341729T3 (es) | 2010-06-25 |
| CA2604803A1 (en) | 2006-10-19 |
| PL1889920T3 (pl) | 2010-06-30 |
| MX2007012668A (es) | 2008-03-11 |
| US20110269948A1 (en) | 2011-11-03 |
| KR20080080430A (ko) | 2008-09-04 |
| WO2006108905A1 (es) | 2006-10-19 |
| PT1889920E (pt) | 2010-04-14 |
| EP1889920B1 (de) | 2010-01-06 |
| RU2007141930A (ru) | 2009-05-20 |
| BRPI0607507A2 (pt) | 2009-09-08 |
| CN101405403A (zh) | 2009-04-08 |
| DE602006011607D1 (de) | 2010-02-25 |
| EP1889920A1 (de) | 2008-02-20 |
| EP2246441B1 (de) | 2015-12-16 |
| US20140023657A1 (en) | 2014-01-23 |
| CN101405403B (zh) | 2013-07-10 |
| US8901096B2 (en) | 2014-12-02 |
| JP4759612B2 (ja) | 2011-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1111714T1 (el) | Δεσμευτικες πρωτεϊνες αυξητικου παραγοντα ηπατοκυτταρων (hgf). | |
| WO2020093006A8 (en) | Methods of treating cancer in biomarker-identified patients with non-covalent inhibitors of cyclin-dependent kinase 7 (cdk7) | |
| CY1122973T1 (el) | Συνθεση υγρου διαπιδυσης η οποια περιλαμβανει ουσιες αναστολης της κρυσταλλωσης | |
| ECSP088440A (es) | Imidazopirazinas como inhibidores de proteinquinasa | |
| NO20055894L (no) | Fremgangsmater og blandinger for behandling av amyloidrelatertere sykdommer | |
| EA200900802A1 (ru) | Способы и композиции для лечения амилоидных заболеваний | |
| ATE454465T1 (de) | In-vitro-verfahren zur identifizierung von verbindungen zur krebstherapie | |
| EA201690111A1 (ru) | Имидазопиразиновые ингибиторы тирозинкиназы syk | |
| DE602005019064D1 (de) | Verfahren zur herstellung gefriergetrockneter blutplättchen, gefriergetrocknete blutplättchen enthaltende zusammensetzungen und verwendungsverfahren | |
| BRPI0920261A8 (pt) | Composto, composição farmacêutica, uso do composto, e, método para inibir ou modular atividade de proteína quinase em uma amostra biológica | |
| EA201190043A1 (ru) | Имидазопиразиновые ингибиторы syk | |
| ECSP088350A (es) | Pirazolopirimidinas como inhibidores de protein quinasas | |
| CY1111437T1 (el) | Τετραϋδροπυρρολοπυριμιδινοδιονες και η χρηση τους ως αναστολεων της ανθρωπινης ουδετεροφιλης ελαστασης | |
| CY1114397T1 (el) | Φαρμακευτικες συνθεσεις οι οποιες περιλαμβανουν βακτηρια τα οποια μειωνουν οξαλικα | |
| EP2061907A4 (de) | Tcl1-expression in durch mir-29 und mir-181 regulierter chronischer lymphozyten-leukämie (cll) | |
| EA200802213A1 (ru) | Способы лечения заболеваний крови | |
| CY1110162T1 (el) | Φαρμακοτεχνικη μορφη και μεθοδοι για την αγωγη της θρομβοκυτταραιμιας | |
| CY1117174T1 (el) | ΧΡΗΣΗ 24-norUDCA ΓΙΑ ΤΗΝ ΑΓΩΓΗ ΧΟΛΟΣΤΑΤΙΚΩΝ ΝΟΣΗΜΑΤΩΝ ΤΟΥ ΗΠΑΤΟΣ | |
| ATE497763T1 (de) | Verfahren und reagenzien zur behandlung von entzündlichen erkrankungen | |
| BRPI0507645A (pt) | anticorpo, método de detectar um distúrbio ósseo metabólico, kit para detectar um distúrbio ósseo metabólico, composição farmacêutica para o tratamento de um distúrbio ósseo metabólico, e, método de triar uma substáncia efetiva para tratar e/ou prevenir um distúrbio ósseo metabólico | |
| EA201071422A1 (ru) | Способы лечения заболеваний, связанных с мейотическим кинезином | |
| CY1114811T1 (el) | Νεα κλασματα πρωτεϊνων γαλακτος και η χρηση τους για την προληψη ή τη θεραπεια των χρονιων φλεγμονωδων νοσων | |
| ATE376419T1 (de) | Carbostyril-derivate mit selektiven serotonin- aufnahme inhibitoren, zur behandlung von gemütskrankheiten | |
| CY1116166T1 (el) | Νεα μεθοδος για την αντιμετωπιση λοιμωξεων απο η.pylori | |
| ATE489380T1 (de) | Hydratformen von amg706 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1889920 Country of ref document: EP |